AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03706703
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
Trial: NCT03706703
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
Trial: NCT03706703
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
Trial: NCT01656629
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mcg subq daily for 3 months
Trial: NCT01656629
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 mg weekly for 3 months
Trial: NCT04900948
Drug: Pimecrolimus cream 1%
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
Trial: NCT00359567
Drug: palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Trial: NCT00359567
Drug: granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Trial: NCT01219933
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
Trial: NCT01219933
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: background therapy: 8 mg/kg iv every 4 weeks
Trial: NCT00657384
Drug: acid tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
Trial: NCT02911688
Drug: gamma tocopherol
RxNorm normalized name: Gamma tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
Trial: NCT01837667
Drug: LB-100 for Injection
RxNorm normalized name: milbemycin oxime
DrugBank: LB-100 (DB15412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
Trial: NCT01837667
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
Trial: NCT04218071
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib at protocol-specified doses for given platelet count
Trial: NCT04218071
Drug: 9-ING-41
RxNorm normalized name: ING-1
DrugBank: ING-1 (DB05831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-
Trial: NCT00680758
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients
Trial: NCT00680758
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients
Trial: NCT00680758
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients
Trial: NCT03149003
Drug: DSP-7888 Dosing Emulsion
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
Trial: NCT03149003
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
Trial: NCT02177409
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00975065
Drug: vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: vildagliptin 50 mg bid plus metformin 1500mg
Trial: NCT00975065
Drug: metformin 1500mg plus metformin 500mg or 1000mg (Diabex)
RxNorm normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 1500mg plus metformin 500mg or 1000mg
Trial: NCT02916147
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02916147
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02634021
Drug: dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous loading of dexmedetomidine for 1 mcg/kg
Trial: NCT02634021
Drug: midazolam group
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous loading of midazolam for 0.1 mg/kg
Trial: NCT00927615
Drug: abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg body weight (intracoronary)
Trial: NCT00927615
Drug: abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg body weight (intravenous)
Trial: NCT04172961
Drug: nanomicellular cyclosporine 0.09%
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Trial: NCT04172961
Drug: Lifitegrast
RxNorm normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Trial: NCT00987493
Drug: bendamustine hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
Trial: NCT00987493
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
Trial: NCT00376701
Drug: Avastin (Bevacizumab)
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avastin 1.25 mg intravitreal
Trial: NCT00376701
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal 1.25 mg
Trial: NCT00376701
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
Trial: NCT04287686
Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)
RxNorm normalized name: Recombinant Human Angiotensin-Converting Enzyme 2
DrugBank: Alunacedase alfa (DB15736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
Trial: NCT00566865
Drug: placebo for gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mitiglinide + placebo for gemfibrozil 600 mg bid
Trial: NCT00566865
Drug: gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitiglinide + 600 mg gemfibrozil bid
Trial: NCT01172756
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg single oral dose
Trial: NCT03801746
Drug: vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral dose 300 mg
Trial: NCT03801746
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Rifampin
Trial: NCT03801746
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Probenecid
Trial: NCT03801746
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cyclosporine
Trial: NCT00385398
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
Trial: NCT00385398
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
Trial: NCT03738059
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will receive intravenous Dexmedetomidine
Trial: NCT00363727
Drug: ropinirole controlled-release (REQUIP CR) for RLS
RxNorm normalized name: ropinirole Extended Release Oral Tablet
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01172756
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg single oral dose
Trial: NCT01172756
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg single oral dose
Trial: NCT01813838
Drug: ACADESINE 140mg/kg/d
DrugBank: Acadesine (DB04944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d
Trial: NCT01813838
Drug: ACADESINE 210mg/kg/d
DrugBank: Acadesine (DB04944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d
Trial: NCT01813838
Drug: ACADESINE 315mg/kg/d
DrugBank: Acadesine (DB04944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d
Trial: NCT00849602
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine bid for three days
Trial: NCT00219115
Drug: aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01486576
Drug: Voluven (Hydroxyethyl starch 130/0,4)
RxNorm normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Trial: NCT01486576
Drug: Sodium Chloride 9 mg/ml
RxNorm normalized name: sodium chloride 9 MG/ML
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Trial: NCT01936389
Drug: AR-12286
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00690807
Drug: PH-10
RxNorm normalized name: RPH-104
DrugBank: Goflikicept (DB16396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
Trial: NCT01776671
Drug: Gralise
RxNorm normalized name: Gralise
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
Trial: NCT03371173
Drug: Ferric maltol 30 mg (Feraccru®)
RxNorm normalized name: ferric maltol 30 MG
DrugBank: Ferric maltol (DB15598)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Trial: NCT02124772
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
Trial: NCT02124772
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
Trial: NCT03964753
Drug: Nab-paclitaxel and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
Trial: NCT02827500
Drug: ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active Comparator: ivabradine
Trial: NCT02310048
Drug: MT-1303-FormB
RxNorm normalized name: αMT
DrugBank: Indopan (DB01446)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04493684
Drug: GSK3739937 (PIB)
RxNorm normalized name: C-11 PiB
DrugBank: Pittsburgh Compound B (DB15161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3739937 will be administered as oral suspension.
Trial: NCT03449433
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT03449433
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03781791
Drug: Active Investigational Treatment ENT-01
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENT-01 will be administered in tablet form, once daily.
Trial: NCT02423122
Drug: VX-745
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally-Active Selective P45 MAP Kinase inhibitor
Trial: NCT00276614
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01444586
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
Trial: NCT01943019
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04175925
Drug: BMS-986322
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT04175925
Drug: famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT00099294
Drug: Glufosfamide
RxNorm normalized name: Glufosfamide
DrugBank: Glufosfamide (DB06177)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04117763
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin once daily, for three months
Trial: NCT04276688
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg/100mg twice daily for 14 days
Trial: NCT04276688
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg twice daily for 14 days
Trial: NCT04276688
Drug: Interferon Beta-1B
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25mg subcutaneous injection alternate day for 3 days
Trial: NCT00044889
Drug: clofarabine (IV formulation)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03371953
Drug: Vecuronium
RxNorm normalized name: Vecuronium
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Trial: NCT03371953
Drug: Atracurium
RxNorm normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Trial: NCT03371953
Drug: Vecuronium + Atracurium
DrugBank: Atracurium besylate (DB00732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
Trial: NCT04665115
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04104074
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
Trial: NCT01605318
Drug: Labetuzumab Govitecan (LG)
RxNorm normalized name: sacituzumab govitecan
DrugBank: Labetuzumab govitecan (DB12331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as a slow intravenous (IV) infusion.
Trial: NCT03612323
Drug: Intra-ligamentary Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
Trial: NCT01687244
Drug: INSTILADRIN
RxNorm normalized name: Instiladrin
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Trial: NCT00111540
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
Trial: NCT02789410
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine is administered as part of spinal anesthesia for post-operative pain relief.